Evaluation AIDS dementia complex clinical trials AIDS dementia complex ADC common important causes morbidity infection human immunodeficiency virus type evaluation ADC clinical trials significant clinical impact syndrome value cardinal features index drug efficacy role major clinical end point objectives therapy prevention ADC presymptomatic patient alleviation disease present pathogenesis ADC understood several critical aspects processes clinical manifestations central nervous system CNS infection processes systemic disease clear extent patients necessary therapeutic drug levels CNS Nevertheless assessment ADC prevention treatment relies complementary approach neurological examination diagnosis neuropsychological testing quantitative serial measurement treatment effects surrogate markers cerebrospinal fluid CSF promise objective rapid assessment treatment response dose adjustment Other measurements routine CSF analysis neuroimaging neurophysiological assessments differential diagnosis ADC status experience available antiviral agents ADC period time assessment condition valuable approach antiviral therapy 